Evaxion A/S (NASDAQ:EVAX) Cut to “Hold” at Wall Street Zen

Evaxion A/S (NASDAQ:EVAX) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

EVAX has been the subject of a number of other research reports. Maxim Group began coverage on shares of Evaxion A/S in a report on Thursday, February 19th. They issued a “buy” rating and a $10.00 price target for the company. JonesTrading initiated coverage on Evaxion A/S in a report on Tuesday, March 10th. They set a “buy” rating and a $10.00 price objective on the stock. Lake Street Capital decreased their price objective on Evaxion A/S from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, March 9th. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Evaxion A/S in a research note on Monday, March 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a research report on Friday, January 9th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $11.00.

Evaxion A/S Trading Down 2.3%

Shares of NASDAQ EVAX opened at $3.91 on Friday. Evaxion A/S has a 1-year low of $1.20 and a 1-year high of $12.15. The company has a 50-day moving average of $3.68 and a two-hundred day moving average of $4.67. The company has a market cap of $32.61 million, a PE ratio of -2.96 and a beta of 0.28. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.41.

Hedge Funds Weigh In On Evaxion A/S

Several large investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. bought a new position in Evaxion A/S in the fourth quarter valued at approximately $38,000. Wesbanco Bank Inc. bought a new stake in shares of Evaxion A/S during the 4th quarter valued at $48,000. Finally, SmartHarvest Portfolios LLC bought a new stake in shares of Evaxion A/S during the 4th quarter valued at $72,000. 11.04% of the stock is currently owned by institutional investors and hedge funds.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.